Literature DB >> 29468271

Administrating docetaxel, doxorubicin, and cyclophosphamide as a neoadjuvant treatment may decrease lymphedema risk in breast cancer patients.

Kadri Altundag1.   

Abstract

Entities:  

Year:  2018        PMID： 29468271     DOI： 10.1007/s00520-018-4113-5

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN： 0941-4355            Impact factor:   3.603


× No keyword cloud information.
  2 in total

1.  Adjuvant taxanes and the development of breast cancer-related arm lymphoedema.

Authors:  M Cariati; S K Bains; M R Grootendorst; A Suyoi; A M Peters; P Mortimer; P Ellis; M Harries; M Van Hemelrijck; A D Purushotham
Journal:  Br J Surg       Date:  2015-06-03       Impact factor: 6.939

2.  Changes in volume and incidence of lymphedema during and after treatment with docetaxel, doxorubicin, and cyclophosphamide (TAC) in patients with breast cancer.

Authors:  Janine T Hidding; Carien H G Beurskens; Philip J van der Wees; Wilmy C A M Bos; Maria W G Nijhuis-van der Sanden; Hanneke W M van Laarhoven
Journal:  Support Care Cancer       Date:  2017-11-10       Impact factor: 3.603
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.